Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study

por Goswami, Pushpendra, Oliva, Esther N., Ionova, Tatyana, Else, Roger, Kell, Jonathan, Fielding, Adele K., Jennings, Daniel M., Karakantza, Marina, Al-Ismail, Saad, Collins, Graham P., McConnell, Stewart, Langton, Catherine, Al-Obaidi, Magda J., Oblak, Metod, Salek, Sam
Publicado 2020

Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO

por Goswami, Pushpendra, Oliva, Esther N., Ionova, Tatyana, Else, Roger, Kell, Jonathan, Fielding, Adele K., Jennings, Daniel M., Karakantza, Marina, Al-Ismail, Saad, Collins, Graham P., McConnell, Stewart, Langton, Catherine, Al-Obaidi, Magda J., Oblak, Metod, Salek, Sam
Publicado 2020

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3

por Tornatore, Laura, Capece, Daria, D'Andrea, Daniel, Begalli, Federica, Verzella, Daniela, Bennett, Jason, Acton, Gary, Campbell, Elizabeth A., Kelly, James, Tarbit, Michael, Adams, Nigel, Bannoo, Selina, Leonardi, Antonio, Sandomenico, Annamaria, Raimondo, Domenico, Ruvo, Menotti, Chambery, Angela, Oblak, Metod, Al-Obaidi, Magda J., Kaczmarski, Richard S., Gabriel, Ian, Oakervee, Heather E., Kaiser, Martin F., Wechalekar, Ashutosh, Benjamin, Reuben, Apperley, Jane F., Auner, Holger W., Franzoso, Guido
Publicado 2019